PTGX
Protagonist
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
PTGX Profile
Protagonist Therapeutics, Inc.
A biopharmaceutical company that developing peptide-based new chemical entities for the treatment of inflammatory bowel disease
Pharmaceutical
08/22/2006
08/11/2016
NASDAQ Stock Exchange
126
12-31
Common stock
7700 Gateway Boulevard, Suite 140, Newark, California 94560-1160
--
Protagonist Therapeutics, Inc., incorporated in Delaware on August 22, 2006, is headquartered in Milpitas, California. The company is a biopharmaceutical company, and its new peptide-based chemical entities rusfertide and JNJ-2113 (formerly PN-235) are in different stages of development, both derived from proprietary discovery technology platforms. The company's clinical programs are divided into two categories of diseases: (i) hematological and hematological diseases, and (ii) inflammatory and immunomodulatory diseases.